Summary & Overview
CPT 81269: Alpha Globin (HBA1/HBA2) Duplication/Deletion Analysis
CPT code 81269 represents molecular laboratory testing for duplications and deletions in the alpha globin genes (HBA1/HBA2), used to identify alpha thalassemia and some structural hemoglobinopathies. This genetic assay is clinically important because it helps diagnose inherited causes of anemia, guides genetic counseling, and can influence prenatal and reproductive decision-making. Nationally, such testing is performed primarily in specialized clinical and reference laboratories and is subject to payer coverage policies that vary by insurer and clinical indication.
Key payers commonly referenced in coverage discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context and service setting, an overview of typical payer engagement for this kind of molecular diagnostic, and indicators of what to look for in payer policies and benefit design. The publication also summarizes common modifiers and highlights where data is not available in the input, and it provides links between the clinical purpose of the test and typical laboratory workflows. The content is intended for national audiences — clinical laboratory managers, coding and billing staff, and policy analysts — seeking a clear, practice-oriented description of CPT code 81269.
Billing Code Overview
CPT code 81269 describes a laboratory test in which a lab analyst evaluates a patient specimen for genetic duplications and deletions in the alpha globin 1 and alpha globin 2 (HBA1/HBA2) genes. This testing assesses genetic changes associated with alpha thalassemia and certain structural hemoglobinopathies.
-
Service type: Clinical molecular genetics testing for copy number variation analysis of alpha globin genes
-
Typical site of service: Clinical laboratory or reference molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant woman of Southeast Asian descent presents for prenatal genetic evaluation after routine hemoglobin electrophoresis showed microcytic anemia and a suspected alpha-globin abnormality. The obstetrician orders molecular testing to evaluate for deletions or duplications in the alpha globin genes (HBA1/HBA2) to assess fetal risk for alpha thalassemia and guide counseling. A peripheral blood sample is collected in the outpatient phlebotomy lab, labeled with patient identifiers and requisition indicating pregnancy and abnormal screening results, and shipped to a molecular diagnostics laboratory.
In the laboratory, a molecular technologist performs a targeted copy number analysis (e.g., MLPA or quantitative PCR) of the HBA1 and HBA2 loci. The technical component includes DNA extraction, assay setup, run, and analytic interpretation of duplications and deletions. The laboratory issues a report documenting detected deletions/duplications, method, limitations, and interpretation for carrier status and potential clinical impact. Results are communicated to the ordering obstetrician or genetic counselor for patient counseling and pregnancy management planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the interpretation/reporting by the laboratory director or pathologist separate from the technical assay. |